A support program for people with cancer on immunotherapy
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a program that helps people with cancer manage side effects and find resources for needs like food, transportation, or housing. It is for patients who are starting or recently started immunotherapy for certain cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney, bladder, breast, or lung cancer.
- You are starting or have started a type of immunotherapy (PD-1 or PD-L1 inhibitor) within the past 3 weeks.
- You are 18 years or older.
- You are not pregnant and not nursing.
- You have at least one basic need like food, transportation, or housing.
- You live in the New York metro area (including Long Island, New Jersey, Connecticut, or Pennsylvania) and speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program to improve communication between your cancer team and your regular doctor. If you have heart or diabetes risks and you're being treated for breast, prostate, bladder, or endometrial cancer, this trial may help coordinate your care.
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
This study tests a support program (ICCAN) designed to help people from underserved communities better complete chemotherapy or radiation and improve quality of life. It may help by connecting patients with practical resources and support during treatment.
This trial tests a support program designed to improve quality of life for Chinese cancer patients and survivors. If you qualify, you'll join the program by phone or video call.
This trial tests a program that helps melanoma patients starting immunotherapy track their side effects and get faster access to specialists. The goal is to improve symptom management.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.